Elicio Therapeutics, Inc.
ELTX
Last
$1.89
Day
+4.4%
1y
-83.6%
5y
-90.0%
52w
-88.7%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1232d
EMA 21
1.98
EMA 50
2.65
EMA 200
5.95
20d high
-13.4%
5y high
-92.6%
5y range
1th
Positions held
Your positionsELTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-12
Hold
avoid
Signal
Sell
Target
$2.01
Stop
$1.64
Stop distance
13.2%
Target vs last
+6.3%
Fundamentals
| Market cap | $47.57M | Enterprise value | $38.24M | Trailing P/E | — | Forward P/E | -1.07 |
| PEG | — | Price / book | 5.00 | Beta | 1.98 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -7.7% | ROA | -77.9% | Debt / equity | 1.78 |
| Current ratio | 2.77 | Free cash flow | -$22.32M | Analyst recommendation | strong_buy | Mean target | $13.67 |
| 52w high | $16.00 | 52w low | $1.71 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$8.2M | -$11.8M | -$7.7M | -$10.1M | -$10.6M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$10.4M | -$10.6M | -$8.8M | -$8.0M | -$9.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$39.6M | -$51.9M | -$35.2M | -$28.2M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$37.3M | -$45.0M | -$35.7M | -$23.7M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-24 · B. Riley Adjusts Price Target on Elicio Therapeutics to $8 From $27, Keeps Buy Rating
2026-08-31 · Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-24 · Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
2026-08-13 · Elicio Therapeutics: Q2 Earnings Snapshot
2026-08-13 · Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Price (daily)
Full chart · RSI · MACD · patternsELTX · daily-3.2% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin